Total item
Cart Subtotal
$0.00 - Czech J, .et al. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation, Leukemia, 2018, Nov 23 PMID: 30470838
Biological Activity
INCB39110 is a potent JAK1 tyrosine kinase inhibitor, which is currently in Phase II trials for the treatment of rheumatoid arthritis, myelofibrosis, rheumatoid arthritis and plaque psoriasis.
| In vitro | DMSO | 88 mg/mL (158.98 mM) | |
| Water | Insoluble | ||
| Ethanol | 88 mg/mL (158.98 mM) | ||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 18.07 mL | 90.33 mL | 180.67 mL |
| 0.5 mM | 3.61 mL | 18.07 mL | 36.13 mL |
| 1 mM | 1.81 mL | 9.03 mL | 18.07 mL |
| 5 mM | 0.36 mL | 1.81 mL | 3.61 mL |
*The above data is based on the productmolecular weight 553.51. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Catalog Num | A14390 |
|---|---|
| Actions | Inhibitor |
| CAS No. | 1334298-90-6 |
| Formula | C26H23F4N9O |
| M. Wt | 553.51 |
| Purity | >98% |
| Synonyms | INCB 39110, INCB-39110, INCB039110, INCB-039110, INCB 039110 |
| SMILES | N#CCC1(N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2)CN(C5CCN(C(C6=C(F)C(C(F)(F)F)=NC=C6)=O)CC5)C1 |
| Storage | Store lyophilized at -20ºC, keep desiccated. |
Datasheet
Product Tags
Product Questions
Product Questions
No Questions
Keywords:buy INCB39110 (Itacitinib) | INCB39110 (Itacitinib) Supplier | purchase | cost | manufacturer | order | distributor | buy 1334298-90-6| 1334298-90-6 Supplier | purchase 1334298-90-6 | 1334298-90-6 cost | 1334298-90-6 manufacturer | order 1334298-90-6 | 1334298-90-6 distributor
Adooq Quality Guarantee
We promise all products perform as described.